Source: International Congress 2017 – TB: co-morbidities and outcome
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. Clerigo (LISBOA, Portugal). Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country. 2723

Member's Comments

No comment yet.

Related content which might interest you: The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Quality of sleep and psychiatric parameters in patients with HIV infection on highly active antiretroviral therapy (HAART) Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009 Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004 Treatment outcomes of MDR-TB and HIV co-infection in Europe Source: Eur Respir J, 49 (6) 1602363; 10.1183/13993003.02363-2016 Year: 2017 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen Source: Eur Respir J 2003; 21: 785-788 Year: 2003 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Source: Eur Respir J 2005; 25: 751-757 Year: 2005 Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Predictors of death in patients with MDR-TB and HIV Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 South African patients with extensively drug-resistant tuberculosis have poor outcomes regardless of HIV status Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Functional and memory status of M. tuberculosis specific T-cells in HIV-infected patients naïve to antiretroviral treatment Source: International Congress 2014 – Future frontiers in the diagnosis of Mycobacterium tuberculosis infection Year: 2014 High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons Source: International Congress 2015 – Screening strategies in TB Year: 2015 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Features of TB/HIV co-infection and treatment outcome Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010